Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
Year: 2019
Type: article
Study design: Clinical Trial
Authors: Courtney D. DiNardo, Gail J. Roboz, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Institutions: The University of Texas MD Anderson Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, The Ohio State University Wexner Medical Center, Johns Hopkins Hospital, Northwestern University, Emory University, Winship Cancer Institute, Sarah Cannon, University of Alabama at Birmingham, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Colorado Anschutz, City Of Hope National Medical Center, Washington University in St. Louis, University of Miami, Sylvester Comprehensive Cancer Center, Massachusetts General Hospital, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2970178583